Advertisement
U.S. markets open in 5 hours 17 minutes
  • S&P Futures

    4,978.25
    -13.25 (-0.27%)
     
  • Dow Futures

    38,542.00
    -100.00 (-0.26%)
     
  • Nasdaq Futures

    17,525.75
    -81.50 (-0.46%)
     
  • Russell 2000 Futures

    2,003.10
    -7.10 (-0.35%)
     
  • Crude Oil

    76.58
    -0.46 (-0.60%)
     
  • Gold

    2,037.40
    -2.40 (-0.12%)
     
  • Silver

    23.08
    -0.05 (-0.22%)
     
  • EUR/USD

    1.0796
    -0.0016 (-0.15%)
     
  • 10-Yr Bond

    4.2750
    0.0000 (0.00%)
     
  • Vix

    15.74
    +0.32 (+2.08%)
     
  • GBP/USD

    1.2605
    -0.0020 (-0.16%)
     
  • USD/JPY

    150.0970
    +0.1710 (+0.11%)
     
  • Bitcoin USD

    51,465.61
    -290.80 (-0.56%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,665.30
    -53.91 (-0.70%)
     
  • Nikkei 225

    38,262.16
    -101.45 (-0.26%)
     

Delcath Systems to Participate at the Roth MKM 2023 Healthcare Opportunities Conference on October 12, 2023

NEW YORK, Oct. 3, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the Roth MKM Healthcare Opportunities Conference in New York. Delcath CEO, Gerard Michel will present on October 12 at 11:45 AM ET.

Delcath Systems, Inc. (PRNewsfoto/Delcath Systems, Inc.)
Delcath Systems, Inc. (PRNewsfoto/Delcath Systems, Inc.)

A webcast of the presentation will be available at ROTH - 2023 Healthcare Opportunities Conference | Sequire Events. A replay of the presentation will be available following the event.

Management is scheduled to host one-on-one meetings throughout the event. Investors interested in arranging one-on-one meetings should contact your conference representative. You may also call or email Ben Shamsian of Lytham Partners at 646-829-9701, or shamsian@lythampartners.com.

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (melphalan for Injection/Hepatic Delivery System), approved for use in the United States by FDA, and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), designated under the medical device regulation for use in Europe and the United Kingdom, are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. For more information regarding HEPZATO KIT and its use, including Important Safety Information and Boxed Warning, please visit HEPZATOKIT.com. For more information regarding CHEMOSAT and its use, please visit Chemosat.com.

Contact:
Investor Relations Contact:
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com

 

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/delcath-systems-to-participate-at-the-roth-mkm-2023-healthcare-opportunities-conference-on-october-12-2023-301945163.html

SOURCE Delcath Systems, Inc.

Advertisement